Christopher Paul Simms - 16 Dec 2021 Form 4 Insider Report for IVERIC bio, Inc.

Role
SVP, Chief Commercial Officer
Signature
/s/ Todd Anderman, as Attorney-in-Fact for Christopher Simms
Issuer symbol
N/A
Transactions as of
16 Dec 2021
Net transactions value
$0
Form type
4
Filing time
20 Dec 2021, 15:34:58 UTC
Previous filing
22 Nov 2021
Next filing
04 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ISEE Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 16 Dec 2021 Common Stock 50,000 $14.83 Direct F1
transaction ISEE Restricted Stock Units Award $0 +25,000 $0.000000 25,000 16 Dec 2021 Common Stock 25,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the stock option award will vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares, in approximately equal monthly installments through the fourth anniversary of the grant date.
F2 Restricted stock units converted into common stock on a one-for-one basis upon vesting of the units.
F3 Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award in annual installments (on January 2, 2023, January 2, 2024, January 2, 2025 and January 2, 2026).